je.st
news
KEYTRUDA (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
2015-10-28 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product. Language: English Contact: Media:Pamela Eisele, 267-305-3558 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: product
usa
prix
award
Category:Biotechnology and Pharmaceuticals